Rising demand for weight-loss therapies reshapes India’s metabolic health landscape
The anti-obesity drug market in India is witnessing unprecedented growth, with Eli Lilly’s Mounjaro (tirzepatide) surpassing ₹50 crore in sales within 90 days of its launch. The surge in demand reflects India’s growing obesity epidemic and increasing acceptance of medical weight management solutions.
Mounjaro’s Rapid Growth in India
- Mounjaro, primarily prescribed for type 2 diabetes and weight loss, saw its sales climb from ₹13 crore in May to ₹26 crore in June 2025 alone.
- The drug’s success is driven by both physician adoption and increasing patient awareness of medical options for metabolic diseases.
Novo Nordisk’s Wegovy Enters the Fray
Novo Nordisk, the maker of Wegovy (semaglutide), has also launched its anti-obesity treatment in India, intensifying competition in the weight management therapeutics market.
- Analysts expect Wegovy to capture a significant share due to its global success in weight loss therapy.
- The rivalry between Eli Lilly and Novo Nordisk mirrors trends seen in the U.S. and Europe.
India’s Growing Obesity Crisis
- Nearly 135 million Indians are living with obesity, according to public health estimates.
- With lifestyle diseases on the rise, India is emerging as a critical market for GLP-1 receptor agonists, the drug class to which both Mounjaro and Wegovy belong.
Market Outlook
- Experts predict India’s medical weight loss market could grow to ₹2,000 crore ($240 million) over the next five years.
- Widening insurance coverage and telehealth-based obesity management platforms may further accelerate adoption.
Source Inspiration: The Economic Times – Mounjaro crosses ₹50 crore in India in 90 days as Wegovy joins fray
